Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters

Atif Ali Hashmi¹*, Ghazala Mudassir², Rozina Nooreen Hashmi³, Muhammad Irfan⁴, Huda Asif⁵, Erum Yousuf Khan¹, Syed Muhammad Abu Bakar¹, Naveen Faridi¹

Abstract

Objective: We aimed to investigate the frequency of microsatellite instability (MSI) in endometrial carcinoma in our population and its association with clinico-pathologic features. Methods: A total of 126 cases of primary endometrial carcinoma were included in the study that underwent surgical resections. All slides of these cases were reviewed and representative paraffin fixed tissue blocks were selected for MLH1, MSH2, MSH6 and PMS2 IHC staining. IHC expression was categorized into five groups: no loss of expression; loss of expression of all four antibodies; combined loss of MLH1/PMS2; combined loss of MSH2/MSH6; and isolated loss of MLH1. Pathological records of all cases were retrieved from patient files. Result: Abnormal expression of MSI was noted in 56 cases (44.4%) among which 16 cases showed loss of nuclear expression of all markers, 34 cases showed loss of MLH1/PMS2 expression, 4 cases showed loss of MSH2/MSH6 while only 2 cases revealed isolated loss of MLH1. Pathological records of all cases were retrieved from patient files. Result: Abnormal expression of MSI was noted in 56 cases (44.4%) among which 16 cases showed loss of nuclear expression of all markers, 34 cases showed loss of MLH1/PMS2 expression, 4 cases showed loss of MSH2/MSH6 while only 2 cases revealed isolated loss of MLH1. Personal and family history suggestive of inherited cancer susceptibility was revealed in 11 cases most of which were associated with MSH2/MSH6 loss. Significant association of MSI expression was found with tumor stage and personal/family history of endometrial/colon cancer. Conclusion: A high frequency of endometrioid cancers in our study showed abnormal expression of MSI markers, most of which depicted MLH1/PMS2 loss and were not associated with inherited cancer susceptibility. On the other hand, a minority of cases showed loss of all MSI markers or MSH2/MSH6 loss and were significantly associated with family/personal history of cancer. Therefore, we suggest that epigenetic changes in MLH1 locus may be a predominant pathway of tumorigenesis in our population rather than inherited mutation of MSI genes; however more large scale studies with genetic testing are required to validate this observation.

Keywords: Microsatellite Instability (MSI)- endometrial carcinoma- Lynch syndrome- hereditary

Asian Pac J Cancer Prev, 20 (9), 2601-2606

Introduction

Microsatellite Instability (MSI) has emerged as one of the major pathways in endometrial carcinogenesis (McMeekin et al., 2016). Microsatellites are short segments of repetitive DNA sequences found predominantly in non-coding DNA of human genome. MSI leads to an increased propensity to develop changes in the number of repeat elements as compared with normal tissue due to DNA repair errors made during replication (Kolodner and Marsischky, 1999; Esteller et al., 1998). High levels of MSI called as MSI-high measured in the DNA of tumor cells compared with normal tissue DNA occur due to one of two possible causes. These include germline or sporadic mutation in at least one of the DNA mismatch repair enzymes (MLH1, PMS2, MSH2, and MSH6) and epigenetic silencing due to MLH1 gene promoter hypermethylation.

MSI is usually found in endometrioid endometrial cancers. On the other hand, non-endometrioid endometrial cancers show genetic instability at chromosomal level due to primary defects in p53 gene, rather than microsatellite level. MSI in endometrial cancers secondary to sporadic mutations or epigenetic silencing has been estimated to occur in approximately 15-20% of endometrial cancers; whereas, germline mutations account for approximately 5% of endometrial cancers (Gruber and Thompson, 1996; Dunlop et al., 1997). These germline mutations in mismatch repair genes lead to a site specific genetic predisposition of cancers referred to as Lynch syndrome or hereditary non-polyposis colorectal cancer (HNPPC) syndrome. Apart from an increased risk of colorectal
carcinoma, women with HNPCC have a substantial increase in risk of developing endometrial cancer (40-60% life time risk with MLH1 and MSH2 mutations, 71% risk with MSH2 mutations) (Aarnio et al., 1999; Hendriks et al., 2004; Watson et al., 2008). Risk for other cancers is also increased including lower urinary tract, ovary, stomach and small bowel (Watson et al., 2008). Although genetic testing remains gold standard for detection of MSI, loss of expression of mismatch repair enzymes MLH1, PMS2, MSH2 and MSH6 by immunohistochemistry (IHC) may be used as a surrogate marker for MSI (Hashmi et al., 2018). To date, there is limited data to suggest that MSI-high endometrial cancers are prognostically favorable or worse as compared to chromosomally instable endometrial cancers. Furthermore, histologic parameters of these tumors has not yet been studied in our population, therefore we aimed to investigate the frequency of MSI in endometrioid endometrial carcinoma in our population and its association with clinico-pathologic features using a four antibody panel.

Materials and Methods

A total of 126 cases of primary endometrial carcinomas were included in the study. All patients underwent surgical resections between January 2014 and December 2015 at Liaquat National Hospital, Karachi, Pakistan. All cases were biopsy proven. Patients with history of pre-operative chemotherapy or radiation therapy were excluded from the study. Moreover, cases with non-endometrioid histology were also excluded. Medical reports of the patients were reviewed and patients were called to reveal personal and family history of cancers suggestive of inherited cancer susceptibility. The study was approved by the hospital ethical committee.

All slides of these cases were retrieved and reviewed. Then representative paraffin fixed tissue blocks were selected for IHC staining that showed both tumor and adjacent non-cancerous endometrium. Immunohistochemistry with MLH1, MSH2, MSH6 and PMS2 was performed by using Dako envision method on representative paraffin fixed tissue blocks according to manufacturers protocols. IHC was performed manually in batches of 10 with positive and negative controls run along each batch. Normal colonic tissue is used as positive control. Known case of microsatellite instable colorectal cancer is used as negative control. Microarrays were not used. Any nuclear staining in tumor cells was taken as no loss of expression; on the other hand, loss of expression was interpreted when there was no nuclear staining for any one of the antibody as per College of American Pathologists (CAP) guidelines. IHC expression was then categorized into five groups: no loss of expression; loss of expression of all four antibodies; combined loss of MLH1/ PMS2; combined loss of MSH2/MSH6; and isolated loss of MLH1 as shown in Figures 1 and 2. Pathological records of all cases were retrieved from patient files. In addition, all retrieved slides were independently reviewed by two histopathologists.

Statistical analysis

Statistical package for social sciences (SPSS 21) was used for analysis. Mean and standard deviation were calculated for quantitative variables. Frequency and percentage were evaluated for qualitative variables. Chi square test was applied to determine association. P-value of ≤0.05 was taken as significant.

Results

Mean age of the patients included in the study was 55.10 (34-70) years. Majority of the patients were above 50 years of age (65.9%) and most of the patients were post-menopausal (86.5%). FIGO stage I (T1N0) was the most frequent stage at presentation (61.9%) and cervical or adnexal involvement was noted in a minority of cases (31.7% and 9.5% respectively). Similarly, a minority of cases were found to be at high grade/ grade III (7.1%). Overall 11 cases had personal or family history of cancers, out of which 4 patients had family history of endometrial carcinoma, 3 had family history of colorectal carcinoma, 2 had family history of pancreato-biliary cancer and 2 had synchronous colorectal carcinoma. Abnormal expression of MSI was noted in 56 cases (44.4%) among which 16

Figure 1. Frequency of Expression of Microsatellite Instability (MSI) Markers in the Studied Population

2602 Asian Pacific Journal of Cancer Prevention, Vol 20
Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry

In the current study, we evaluated MSI status of endometrial cancers in Pakistani patients. Endometrial cancers are a major cause of morbidity and mortality in SouthAsia (Tanvir et al., 2014; Hashmi et al., 2018).

Table 1. Expression of Microsatellite Instability (MSI) Markers in Endometrial Carcinoma and Its Association with Clinicopathologic and Prognostic Parameters

|                          | Intact expression of all markers (n=70) | Loss of expression of all markers (n=16) | MLH1/PMS2 Loss of expression (n=34) | MSH2/MSH6 Loss of expression (n=4) | Isolated MLH1 loss of expression (n=2) | Total (n=126) | P-value |
|--------------------------|----------------------------------------|----------------------------------------|------------------------------------|------------------------------------|----------------------------------------|---------------|---------|
| Age Group                |                                        |                                        |                                    |                                    |                                        |               |         |
| <50 yrs                  | 24 (34.3)                              | 7 (41.2)                               | 10 (30.3)                          | 2 (50)                             | 0 (0)                                  | 43 (34.1)     | 0.784** |
| >50 yrs                  | 46 (65.7)                              | 10 (58.8)                              | 23 (69.7)                          | 2 (50)                             | 2 (100)                                | 83 (65.9)     |         |
| Menopausal Status        |                                        |                                        |                                    |                                    |                                        |               |         |
| Pre Menopausal           | 10 (14.3)                              | 3 (17.6)                               | 4 (12.1)                           | 0 (0)                              | 0 (0)                                  | 17 (13.5)     | 0.946** |
| Post Menopausal          | 60 (85.7)                              | 14 (82.4)                              | 29 (87.9)                          | 4 (100)                            | 2 (100)                                | 109 (86.5)    |         |
| Tumor (T) Stage          |                                        |                                        |                                    |                                    |                                        |               |         |
| T1                       | 44 (62.9)                              | 8 (47.1)                               | 25 (75.8)                          | 2 (50)                             | 2 (100)                                | 81 (63.4)     | 0.012*  |
| T2                       | 13 (18.6)                              | 7 (41.2)                               | 6 (18.2)                           | 0 (0)                              | 0 (0)                                  | 26 (20.6)     |         |
| T3                       | 13 (18.6)                              | 0 (0)                                  | 2 (6.1)                            | 2 (50)                             | 0 (0)                                  | 17 (13.5)     |         |
| T4                       | 0 (0)                                  | 2 (11.8)                               | 0 (0)                              | 0 (0)                              | 0 (0)                                  | 2 (1.6)       |         |
| Nodal (N) Stage          |                                        |                                        |                                    |                                    |                                        |               |         |
| N0                       | 70 (100)                               | 15 (88.2)                              | 33 (100)                           | 2 (50)                             | 2 (100)                                | 122 (96.8)    | 0.000*  |
| N1                       | 0 (0)                                  | 2 (11.8)                               | 0 (0)                              | 0 (0)                              | 0 (0)                                  | 2 (1.6)       |         |
| N2                       | 0 (0)                                  | 0 (0)                                  | 0 (0)                              | 2 (50)                             | 0 (0)                                  | 2 (1.6)       |         |
| FIGO Stage               |                                        |                                        |                                    |                                    |                                        |               |         |
| Stage I                  | 41 (58.6)                              | 8 (47.1)                               | 25 (75.8)                          | 2 (50)                             | 2 (100)                                | 78 (61.9)     | 0.014*  |
| Stage II                 | 15 (22.9)                              | 7 (41.2)                               | 6 (18.2)                           | 0 (0)                              | 0 (0)                                  | 29 (23)       |         |
| Stage III                | 13 (18.6)                              | 0 (0)                                  | 2 (6.1)                            | 2 (50)                             | 0 (0)                                  | 17 (13.5)     |         |
| Stage IV                 | 0 (0)                                  | 2 (11.8)                               | 0 (0)                              | 0 (0)                              | 0 (0)                                  | 2 (1.6)       |         |
| FIGO Grade               |                                        |                                        |                                    |                                    |                                        |               |         |
| Grade I                  | 30 (42.9)                              | 7 (41.2)                               | 15 (45.5)                          | 2 (50)                             | 2 (100)                                | 56 (44.4)     | 0.824** |
| Grade II                 | 33 (47.1)                              | 10 (58.8)                              | 16 (48.5)                          | 2 (50)                             | 0 (0)                                  | 61 (48.4)     |         |
| Grade III                | 7 (10)                                 | 0 (0)                                  | 2 (6.1)                            | 0 (0)                              | 0 (0)                                  | 9 (7.1)       |         |
| Cervical Invasion        |                                        |                                        |                                    |                                    |                                        |               |         |
| Present                  | 23 (32.9)                              | 9 (52.9)                               | 6 (18.2)                           | 2 (50)                             | 0 (0)                                  | 40 (31.7)     | 0.077** |
| Absent                   | 47 (67.1)                              | 8 (47.1)                               | 27 (81.8)                          | 2 (50)                             | 2 (100)                                | 86 (68.3)     |         |
| Adnexal Involvement      |                                        |                                        |                                    |                                    |                                        |               |         |
| Present                  | 10 (14.3)                              | 0 (0)                                  | 0 (0)                              | 2 (50)                             | 0 (0)                                  | 12 (9.5)      | 0.007*  |
| Absent                   | 60 (85.7)                              | 17 (100)                               | 33 (100)                           | 2 (50)                             | 2 (100)                                | 114 (90.5)    |         |
| Lymphovascular Invasion  |                                        |                                        |                                    |                                    |                                        |               |         |
| Present                  | 4 (5.7)                                | 0 (0)                                  | 2 (6.1)                            | 0 (0)                              | 0 (0)                                  | 6 (4.8)       | 0.796** |
| Absent                   | 66 (94.3)                              | 17 (100)                               | 31 (93.9)                          | 4 (100)                            | 2 (100)                                | 120 (95.2)    |         |
| Medical/family history of endometrial/colon cancer | | | | | | | |
| Present                  | 0 (0)                                  | 7 (43.8)                               | 2 (5.9)                            | 2 (50)                             | 0 (0)                                  | 11 (8.7)      | 0.000*  |
| Absent                   | 70 (100)                               | 9 (56.3)                               | 32 (94.1)                          | 2 (50)                             | 2 (100)                                | 115 (91.3)    |         |
| Recurrence               |                                        |                                        |                                    |                                    |                                        |               |         |
| Yes                      | 12 (17.1)                              | 6 (37.5)                               | 4 (11.8)                           | 1 (25)                             | 0 (0)                                  | 23 (18.3)     | 0.218** |
| No                       | 58 (82.9)                              | 10 (62.5)                              | 30 (88.2)                          | 3 (75)                             | 2 (100)                                | 103 (81.7)    |         |

*P-value is significant at 95% confidence interval

Most of the cases with personal or family history of cancers showed MSH2/MSH6 loss of expression as shown in Table 1 (P value <0.001). Similarly, significant association of MSI expression was found with tumor stage, nodal Stage, FIGO stage, adnexal involvement and medical/family history of endometrial/colon cancer as shown in Table 1. Cases with loss of expression of all MSI markers were found to be at higher TNM/ FIGO stage compared to cases showing intact expression of all markers; however no significant association of MSI was seen with tumor grade or tumor recurrence.

Discussion

In the current study, we evaluated MSI status of endometrial cancers in Pakistani patients. Endometrial cancers are a major cause of morbidity and mortality in SouthAsia (Tanvir et al., 2014; Hashmi et al., 2018).
To our knowledge this is the first study evaluating MSI status in our population. Abnormal expression of MSI in our population was turned out to be 44% which is quite high compared to studies conducted in other parts of the world. Frequency of MSI+ endometrial cancers is quite variable. A study conducted in USA involving 473 cases of endometrial cancers revealed 20% MSI+ tumors. They found MSI+ tumors to be associated with more favorable outcome despite being linked to prognostically poor histologic parameters like pathologic stage and grade (Black et al., 2006). It has been well established that, MSI is specifically linked to endometrioid histology (Catasus et al., 1998), therefore we excluded non-endometrioid endometrial cancers from our study. An NRG oncology/gynecology group study, in a large series of cases, assigned 1,024 cases into four MMR classes and found that MMR defects were linked to poor prognostic factors like higher grade, myometrial invasion and lymphovascular invasion. On the other hand, there was no significant difference in survival of these patients and they suggested that immune surveillance associated with MMR defects may counteract the effects of negative prognostic factors in these patients (Mc Meekin et al., 2016). Similarly in another study MSI- high status was detected in 15.6% endometrial cancers while no statistically significant differences between patients with MSI-high and MSI stable tumors was found after stage, histology and tumor grade adjustment on multivariate analysis (Kanopiene et al., 2014). Our results are concordant with these findings as we found association of MSI+ endometrial cancers with high TNM/FIGO stage, however there was no association found with disease free survival. Histologic features of MSI high tumors include poor differentiation, intra-tumoral and peri-tumoral lymphocytic reaction in colorectal cancers; however they are not validated in endometrial cancers.

In our study, tumors with dMMR status accounted for 44% of total cases. Only a few studies have been conducted in SouthAsia evaluating MSI in endometrial cancers. A study conducted in India revealed 30% frequency of MSI in endometrial cancers; however they didn’t excluded non-endometrioid cancers from their study, which may be the reason of this difference (Kunitomi et al., 2017). Concurrent loss of MLH1/PMS2 was the most common pattern of abnormal protein expression followed by loss of all markers in our study. A germ-line mutation in one
of the MMR genes is the cause of dMMR in patients with HNPCC (Lynch syndrome) (Zhang et al., 2006). These tumors show high levels of MSI (MSI-H). However a high proportion of sporadic endometrial cancers with no family history also exhibit MSI; on the other hand in sporadic cases, mutation of MMR genes are infrequent whereas biallelic hypermethylation of promoter MLH1 appears to be most important mechanism for inactivation of MMR genes. In a study it was established that 77% of MSI positive cancers showed MLH1 promoter hypermethylation. MLH1 promoter methylation was associated with loss of MLH1 expression with or without concurrent loss of PMS2 expression. On the other hand, loss of MSH2/MSH6 expression was found to be infrequent in these cases. Furthermore, they suggested that MSH2 loss may be linked preferentially to inherited forms of endometrial cancer (cases which are associated with HNPCC) (Simpkins et al., 1999). These findings correlate well with our study in which MLH1/PMS2 loss was the most common pattern while loss of expression of MSH2/MSH6 was seen in a minority of cases and MSH2 loss was significantly associated with inherited cancer susceptibility.

Another significance of MSI testing is therapeutic benefit of anti-PDL therapy in MSI associated endometrial cancers. Role of immune therapy is increasing in many human cancers which express PDL1. It has been proposed that MSI associated endometrial cancers have better response to anti-PDL therapy compared to microsatellite stable endometrial cancers (Howitt et al., 2015).

Our study can be viewed with a few limitations like lack of availability of molecular studies, however the findings of our study may be clinically relevant and may open a door to more large scale studies evaluating genetic makeup of endometrial cancers in our population to validate these findings. High frequency of endometrioid cancers in our study showed abnormal expression of MSI markers, most of which depicted MLH1/PMS2 loss and were not associated with inherited cancer susceptibility. On the other hand, a minority of cases showed loss of all MSI markers or MSH2/MSH6 loss and were significantly associated with family/personal history of endometrial/colon cancer. Therefore, it can be suggested that epigenetic changes in MLH1 locus may be a predominant pathway of tumorigenesis in our population rather than inherited mutation of MSI positive endometrial cancers, however more large scale studies with genetic testing is required to validate this observation.

Acknowledgments

We gratefully acknowledge all staff members of Pathology, Liaquat National Hospital, Karachi, Pakistan for their help and cooperation.

Declarations
Ethics, consent and permissions
Ethics committee of Liaquat National Hospital approved the study. Written informed consent was obtained from the patients for the participation.

Consent to publish
Not applicable.

Availability of data and material
Please contact author for data requests.

Funding
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
Aarnio M, Sankila R, Pukkala E, et al (1999). Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer, 81, 214-8.

Black D, Soslow RA, Levine DA, et al (2006). Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol, 24, 1745-53

Catasus L, Machin P, Matias-Guiu X, Prat J (1998). Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum pathol, 29, 1160-4.

Dunlop MG, Farrington SM, Carathers AD, et al (1997). Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Gen, 6, 105-10.

Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG (1998). MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene, 17, 2413.

Gruber SB, Thompson WD (1996). A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Prev Biomarkers, 5, 411-7.

Hashmi AA, Ali R, Hussain ZF, et al (2017). Mismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parameters. World J Surg Oncol, 15, 116.

Hashmi AA, Hussain ZF, Qadri A, et al (2018). Androgen receptor expression in endometrial carcinoma and its correlation with clinicopathologic features. BMC Res Notes, 11, 289.

Hendriks YM, Wagner A, Morreau H, et al (2004). Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterol,127, 17-25.

Howitt BE, Shukla SA, Sholl LM, et al (2015). Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol, 1, 1319–23.

Kanopiene D, Smailyte G, Vidugiriene J, Bacher J (2014). Impact of microsatellite instability in endometrial carcinomas: clinicopathologic correlation with histopathological parameters. Clin exp Med, 14, 2605.
and mismatch repair deficiency in RER+ tumor cells. Cell, 75, 1227-36.

Simpkins SB, Bocker T, Swisher EM, et al (1999). MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Human Mol Gen, 8, 661-6.

Tanvir I, Riaz S, Hussain A, et al (2014). Hospital-based study of epithelial malignancies of endometrial cancer frequency in lahore, Pakistan and common diagnostic pitfalls. Pathol Res Int, 2014, 179384.

Watson P, Vasen HF, Mecklin JP, et al (2008). The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer, 123, 444-9.

Zhang J, Lindroos A, Ollila S, et al (2006). Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers. Cancer Res, 66, 659-64.